Recent Insider Transactions • May 25
Independent Chair recently bought CA$98k worth of stock On the 21st of May, Daniel Chicoine bought around 174k shares on-market at roughly CA$0.57 per share. This transaction amounted to 67% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Daniel has been a buyer over the last 12 months, purchasing a net total of CA$147k worth in shares. Reported Earnings • May 17
First quarter 2026 earnings released: EPS: CA$0.006 (vs CA$0.007 loss in 1Q 2025) First quarter 2026 results: EPS: CA$0.006 (up from CA$0.007 loss in 1Q 2025). Revenue: CA$21.5m (up 11% from 1Q 2025). Net income: CA$313.0k (up CA$726.0k from 1Q 2025). Profit margin: 1.5% (up from net loss in 1Q 2025). Revenue is forecast to grow 7.9% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare industry in Canada. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 51% per year, which means it is significantly lagging earnings growth. Announcement • May 05
NeuPath Health Inc. to Report Q1, 2026 Results on May 14, 2026 NeuPath Health Inc. announced that they will report Q1, 2026 results Pre-Market on May 14, 2026 Announcement • Mar 31
NeuPath Health Inc., Annual General Meeting, Jun 10, 2026 NeuPath Health Inc., Annual General Meeting, Jun 10, 2026. Reported Earnings • Mar 27
Full year 2025 earnings released: CA$0.013 loss per share (vs CA$0.013 loss in FY 2024) Full year 2025 results: CA$0.013 loss per share (in line with FY 2024). Revenue: CA$87.2m (up 20% from FY 2024). Net loss: CA$717.0k (loss narrowed 1.5% from FY 2024). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 62% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Nov 28
President recently bought CA$60k worth of stock On the 27th of November, Stephen Lemieux bought around 165k shares on-market at roughly CA$0.36 per share. This transaction increased Stephen's direct individual holding by 17x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Stephen has been a buyer over the last 12 months, purchasing a net total of CA$66k worth in shares. Reported Earnings • Nov 16
Third quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0.007 loss in 3Q 2024) Third quarter 2025 results: CA$0.003 loss per share (improved from CA$0.007 loss in 3Q 2024). Revenue: CA$22.1m (up 26% from 3Q 2024). Net loss: CA$153.0k (loss narrowed 62% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Announcement • Oct 27
NeuPath Health Inc. to Report Q3, 2025 Results on Nov 13, 2025 NeuPath Health Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 13, 2025 Reported Earnings • Aug 15
Second quarter 2025 earnings released: EPS: CA$0.005 (vs CA$0.005 in 2Q 2024) Second quarter 2025 results: EPS: CA$0.005 (in line with 2Q 2024). Revenue: CA$23.6m (up 25% from 2Q 2024). Net income: CA$258.0k (down 13% from 2Q 2024). Profit margin: 1.1% (down from 1.6% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Aug 07
NeuPath Health Inc. to Report Q2, 2025 Results on Aug 14, 2025 NeuPath Health Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 14, 2025 New Risk • Jul 31
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.9m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. New Risk • Jun 25
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.7m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Reported Earnings • May 16
First quarter 2025 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 1Q 2024) First quarter 2025 results: CA$0.007 loss per share (in line with 1Q 2024). Revenue: CA$19.3m (up 11% from 1Q 2024). Net loss: CA$413.0k (loss widened 9.3% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Announcement • May 14
NeuPath Health Inc. to Report Q1, 2025 Results on May 15, 2025 NeuPath Health Inc. announced that they will report Q1, 2025 results at 9:30 AM, US Eastern Standard Time on May 15, 2025 Announcement • Apr 15
NeuPath Health Inc. Announces Appointment of Stephen Lemieux, CPA, in the Newly Created Role of President, Effective May 1, 2025 NeuPath Health Inc. announced the appointment of Stephen Lemieux, CPA, in the newly created role of President, effective May 1, 2025. Mr. Lemieux brings more than 20 years of executive experience in the healthcare and biopharmaceutical sectors, with a successful track record in operations, financial strategy and M&A execution. Reporting to the CEO, as President, Mr. Lemieux will lead the implementation of NeuPath's strategy toaccelerate inorganic and organic growth and optimize operating margins. This is expected to involve broadened service offerings, new locations, and acquisitions of existing clinics and their teams. He will also lead the exploration of adjacent markets for opportunities that capitalize on the Company's brand, real estate footprint and operational capabilities. His hiring is the next step in the Company's growth plan, building on the Company's successful financial and operational turnaround and newly secured credit facilities to drive accretive growth. Mr. Lemieux previously served as the Company's Chief Financial Officer and Corporate Secretary from 2019 to 2021, when he spearheaded NeuPath's successful expansion into Alberta. Prior to rejoining NeuPath, he served as CFO at Edesa Biotech and held senior leadership roles at Cipher Pharmaceuticals and Nuvo Pharmaceuticals (now part of Apotex), among others. Mr. Lemieux is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting degree from the University of Toronto. His appointment underscores NeuPath's commitment to building the right leadership team to drive shareholder value through operational excellence and growth. Announcement • Apr 01
NeuPath Health Inc., Annual General Meeting, Jun 11, 2025 NeuPath Health Inc., Annual General Meeting, Jun 11, 2025. Reported Earnings • Mar 28
Full year 2024 earnings released: CA$0.013 loss per share (vs CA$0.002 loss in FY 2023) Full year 2024 results: CA$0.013 loss per share (further deteriorated from CA$0.002 loss in FY 2023). Revenue: CA$72.8m (up 10% from FY 2023). Net loss: CA$728.0k (loss widened CA$621.0k from FY 2023). Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Announcement • Mar 06
NeuPath Health Inc. Performs Its First-Ever Injection of Arthrosamid in North America At Its Mississauga, Ontario NeuPath Health Inc. announced that it has performed the first-ever injection of Arthrosamid in North America at its Mississauga, Ontario clinic. Prior to Health Canada’s approval of Arthrosamid, patients would travel to Europe to access this innovative hydrogel that has been shown to provide up to four years of pain relief for knee osteoarthritis sufferers. Over four million Canadians live with osteoarthritis, with knee osteoarthritis being a leading cause of pain, mobility issues and reduced quality of life. The economic burden of arthritisin Canada was estimated to be $6.4 billion, representing almost one third of the total cost of musculoskeletal diseases. Worldwide, osteoarthritis is a leading cause of disability in older adults. Conventional non-surgical solutions like painkillers and corticosteroid injections provide only temporary relief. The addition of Arthrosamid enables the Company to reinforce its leadership in treatments for chronic pain as it expands its footprint across Canada. Reported Earnings • Nov 17
Third quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.007 profit in 3Q 2023) Third quarter 2024 results: CA$0.007 loss per share (down from CA$0.007 profit in 3Q 2023). Revenue: CA$17.6m (up 9.1% from 3Q 2023). Net loss: CA$401.0k (down 206% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 18
Second quarter 2024 earnings released: EPS: CA$0.005 (vs CA$0.001 in 2Q 2023) Second quarter 2024 results: EPS: CA$0.005 (up from CA$0.001 in 2Q 2023). Revenue: CA$18.9m (up 10% from 2Q 2023). Net income: CA$296.0k (up 284% from 2Q 2023). Profit margin: 1.6% (up from 0.4% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Reported Earnings • May 19
First quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.004 loss in 1Q 2023) First quarter 2024 results: CA$0.007 loss per share (further deteriorated from CA$0.004 loss in 1Q 2023). Revenue: CA$17.5m (up 8.9% from 1Q 2023). Net loss: CA$378.0k (loss widened 97% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Announcement • Mar 30
NeuPath Health Inc., Annual General Meeting, Jun 12, 2024 NeuPath Health Inc., Annual General Meeting, Jun 12, 2024. Reported Earnings • Mar 15
Full year 2023 earnings released: CA$0.002 loss per share (vs CA$0.086 loss in FY 2022) Full year 2023 results: CA$0.002 loss per share (improved from CA$0.086 loss in FY 2022). Revenue: CA$66.1m (up 5.5% from FY 2022). Net loss: CA$107.0k (loss narrowed 97% from FY 2022). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 18
Third quarter 2023 earnings released: EPS: CA$0.007 (vs CA$0.022 loss in 3Q 2022) Third quarter 2023 results: EPS: CA$0.007 (up from CA$0.022 loss in 3Q 2022). Revenue: CA$16.1m (up 5.6% from 3Q 2022). Net income: CA$377.0k (up CA$1.46m from 3Q 2022). Profit margin: 2.3% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Announcement • Sep 07
An unknown buyer completed the acquisition of London medical facility, Ontario from NeuPath Health Inc. (TSXV:NPTH). An unknown buyer agreed to acquire London medical facility, Ontario from NeuPath Health Inc. (TSXV:NPTH) on March 15, 2023. The net proceeds from this sale will be invested in the construction of, and move to, NeuPath's new more modern location, and for working capital and general corporate purposes. The transaction is expected to complete on August 1, 2023.
An unknown buyer completed the acquisition of London medical facility, Ontario from NeuPath Health Inc. (TSXV:NPTH) on September 5, 2023. Reported Earnings • Aug 19
Second quarter 2023 earnings released: EPS: CA$0.001 (vs CA$0.007 loss in 2Q 2022) Second quarter 2023 results: EPS: CA$0.001 (up from CA$0.007 loss in 2Q 2022). Revenue: CA$17.1m (up 7.6% from 2Q 2022). Net income: CA$77.0k (up CA$416.0k from 2Q 2022). Profit margin: 0.4% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Reported Earnings • May 27
First quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0.019 loss in 1Q 2022) First quarter 2023 results: CA$0.004 loss per share (improved from CA$0.019 loss in 1Q 2022). Revenue: CA$16.1m (up 4.2% from 1Q 2022). Net loss: CA$192.0k (loss narrowed 79% from 1Q 2022). Reported Earnings • Apr 01
Full year 2022 earnings released: CA$0.086 loss per share (vs CA$0.072 loss in FY 2021) Full year 2022 results: CA$0.086 loss per share (further deteriorated from CA$0.072 loss in FY 2021). Revenue: CA$62.7m (up 3.0% from FY 2021). Net loss: CA$4.17m (loss widened 29% from FY 2021). Reported Earnings • Nov 18
Third quarter 2022 earnings released: CA$0.022 loss per share (vs CA$0.014 loss in 3Q 2021) Third quarter 2022 results: CA$0.022 loss per share (further deteriorated from CA$0.014 loss in 3Q 2021). Revenue: CA$15.2m (flat on 3Q 2021). Net loss: CA$1.08m (loss widened 64% from 3Q 2021). Board Change • Nov 16
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Director Dan Legault is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 20
NeuPath Health Inc Announces Board Changes NeuPath Health Inc. announced updates to the Company's Board of Directors that will continue to support the Company's leadership team in executing the strategic growth plan. Effective October 19, 2022, Daniel Chicoine has accepted the role of Chair of the Company's Board of Directors, replacing Dianne Carmichael who stepped away for health reasons on September 30, 2022. In addition to the new responsibilities, Mr. Chicoine - as an independent director - will continue to serve as Chair of the Audit Committee and member of the Compensation, Nomination and Corporate Governance Committee. In addition to Mr. Chicoine's appointment to Chair of the Board of Directors, Grishanth Ram resigned from the Board of Directors and all roles with the Company effective today. Mr. Ram is a co-founder of InMedic Creative Medicine, which was acquired by the Company in 2018. Mr. Ram joined the NeuPath Board of Directors in June 2020, when the Company became a reporting issuer. Mr. Chicoine is currently the Chairman of Crescita Therapeutics Inc. and a Director on the Board of Directors of Miravo Healthcare. Mr. Chicoine served as Nuvo's Chairman and Co-CEO and was actively involved in its day-to-day operations from 2004 to 2016 when Crescita became a reporting issuer following the reorganization of Nuvo Research into two separate publicly traded entities, Crescita and Nuvo Pharmaceuticals Inc. Prior to 2004, Mr. Chicoine held various senior executive positions at the Magna International group of companies, including President and Chief Executive Officer and Chief Financial Officer, and was the President of PowerCart Systems Inc., a Markham-based private company that designs and manufactures battery-equipped workstations that power devices with wireless communication capability. Mr. Chicoine is a graduate of the University of Toronto in commerce and is a Chartered Professional Accountant. Reported Earnings • Aug 18
Second quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.025 loss in 2Q 2021) Second quarter 2022 results: CA$0.007 loss per share (up from CA$0.025 loss in 2Q 2021). Revenue: CA$15.9m (flat on 2Q 2021). Net loss: CA$339.0k (loss narrowed 71% from 2Q 2021). Reported Earnings • May 27
First quarter 2022 earnings released: CA$0.019 loss per share (vs CA$0.016 loss in 1Q 2021) First quarter 2022 results: CA$0.019 loss per share (down from CA$0.016 loss in 1Q 2021). Revenue: CA$15.4m (up 8.6% from 1Q 2021). Net loss: CA$907.0k (loss widened 29% from 1Q 2021). Board Change • Apr 27
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Director Dan Legault is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Apr 15
NeuPath Health Inc., Annual General Meeting, Jun 22, 2022 NeuPath Health Inc., Annual General Meeting, Jun 22, 2022. Reported Earnings • Mar 19
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: CA$0.072 loss per share (up from CA$0.21 loss in FY 2020). Revenue: CA$60.9m (up 28% from FY 2020). Net loss: CA$3.23m (loss narrowed 36% from FY 2020). Revenue missed analyst estimates by 11%. Earnings per share (EPS) were also behind analyst estimates. Reported Earnings • Nov 14
Third quarter 2021 earnings released: CA$0.014 loss per share (vs CA$0.01 loss in 3Q 2020) The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: CA$15.2m (up 26% from 3Q 2020). Net loss: CA$660.0k (loss widened 128% from 3Q 2020). Announcement • Aug 18
NeuPath Health Inc. (TSXV:NPTH) completed the acquisition of KumoCare Inc. NeuPath Health Inc. (TSXV:NPTH) agreed to acquire KumoCare Inc. for $1.1 million on June 9, 2021. The acquisition includes 100% of the issued and outstanding shares of Aidly Inc. and KumoCare Peel York Inc. NeuPath has agreed to pay total consideration of up to $1.5 million subject to a net working capital adjustment, payable as follows, $1 million payable in NeuPath shares based on the volume weighted average price for the ten consecutive trading days immediately preceding the closing date and additional cash consideration of up to $0.5 million, based on the achievement of certain operational targets. As part of the KumoCare acquisition, Ben Fagan has agreed to join NeuPath as Chief Technology Officer. Stephen Lemieux, Chief Financial Officer, will resign effective June 30, 2021. The acquisition is subject to customary closing conditions, including approval by the TSX Venture Exchange. The transaction is expected to close in the third quarter of 2021.
NeuPath Health Inc. (TSXV:NPTH) completed the acquisition of KumoCare Inc. on August 17, 2021. Reported Earnings • Aug 13
Second quarter 2021 earnings released The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$15.9m (up 42% from 2Q 2020). Net loss: CA$1.15m (loss narrowed 66% from 2Q 2020). Executive Departure • Jul 13
CFO & Corporate Secretary Stephen Lemieux has left the company On the 30th of June, Stephen Lemieux's tenure as CFO & Corporate Secretary ended after 2.2 years in the role. As of March 2021, Stephen still personally held only 82.50k shares (CA$54k worth at the time). Stephen is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.46 years, which is considered inexperienced in the Simply Wall St Risk Model. Announcement • Jun 10
NeuPath Health Inc. (TSXV:NPTH) agreed to acquire KumoCare Inc. for $1.1 million. NeuPath Health Inc. (TSXV:NPTH) agreed to acquire KumoCare Inc. for $1.1 million on June 9, 2021. The acquisition includes 100% of the issued and outstanding shares of Aidly Inc. and KumoCare Peel York Inc. NeuPath has agreed to pay total consideration of up to $1.5 million subject to a net working capital adjustment, payable as follows, $1 million payable in NeuPath shares based on the volume weighted average price for the ten consecutive trading days immediately preceding the closing date and additional cash consideration of up to $0.5 million, based on the achievement of certain operational targets. As part of the KumoCare acquisition, Ben Fagan has agreed to join NeuPath as Chief Technology Officer. Stephen Lemieux, Chief Financial Officer, will resign effective June 30, 2021. The acquisition is subject to customary closing conditions, including approval by the TSX Venture Exchange. The transaction is expected to close in the third quarter of 2021. Reported Earnings • May 22
First quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.05 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$14.2m (up 22% from 1Q 2020). Net loss: CA$702.0k (loss narrowed 15% from 1Q 2020). Announcement • Apr 23
NeuPath Health Inc. Announces Revenue Guidance for the First Quarter of 2021 NeuPath Health Inc. announced that the company’s revenues for the first quarter of 2021 are anticipated to be in the range of $13.8 to $14.3 million, an increase of approximately 20% over the comparable period in 2020. Revenue for the first quarter includes the acquisition of HealthPointe for the period from February 8th to March 31st. Reported Earnings • Mar 28
Full year 2020 earnings released The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: CA$47.6m (down 4.0% from FY 2019). Net loss: CA$5.06m (loss narrowed 4.7% from FY 2019). Announcement • Feb 10
NeuPath Health Inc. (TSXV:NPTH) acquired Healthpointe Medical Centres Ltd. for CAD 6.7 million. NeuPath Health Inc. (TSXV:NPTH) acquired Healthpointe Medical Centres Ltd. for CAD 6.7 million on February 8, 2021. NeuPath has agreed to pay total cash consideration of up to CAD 4.7 million, payable as follows: (i) CAD 3.2 million upfront cash payment (subject to a working capital adjustment) and (ii) additional cash consideration of up to CAD 1.5 million, based on the achievement of certain financial results over a two-year measurement period. The transaction includes the assumption of approximately CAD 2 million of term debt of HealthPointe. For the 12-month period ended December 31, 2020, HealthPointe generated revenue of approximately CAD 9 million with an Adjusted EBITDA margin of approximately 6%. David Palumbo, Grace-Kim Cho, Stephanie Vaccari, Jeremy Hann, Theo Ling, Peter Clark and David Gadsden from Baker & Mckenzie Llp acted as legal advisor to NeuPath Health Inc. and Bennett Jones LLP acted as legal advisor to HealthPointe.
NeuPath Health Inc. (TSXV:NPTH) completed the acquisition of Healthpointe Medical Centres Ltd. on February 8, 2021. Is New 90 Day High Low • Jan 06
New 90-day low: CA$0.72 The company is down 9.0% from its price of CA$0.79 on 07 October 2020. The Canadian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 6.0% over the same period. Is New 90 Day High Low • Dec 10
New 90-day low: CA$0.75 The company is down 13% from its price of CA$0.86 on 10 September 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 9.0% over the same period. Announcement • Nov 14
NeuPath Health Inc. has completed a Composite Units Offering in the amount of CAD 10.44 million. NeuPath Health Inc. has completed a Composite Units Offering in the amount of CAD 10.44 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 11,600,000
Price\Range: CAD 0.9
Discount Per Security: CAD 0.054 Is New 90 Day High Low • Oct 16
New 90-day high: CA$1.10 The company is up 57% from its price of CA$0.70 on 17 July 2020. The Canadian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 20% over the same period. 
